Kinome inhibition states and multiomics data enable prediction of cell viability in diverse cancer types.


Journal

PLoS computational biology
ISSN: 1553-7358
Titre abrégé: PLoS Comput Biol
Pays: United States
ID NLM: 101238922

Informations de publication

Date de publication:
02 2023
Historique:
received: 23 05 2022
accepted: 20 01 2023
revised: 03 03 2023
pubmed: 23 2 2023
medline: 8 3 2023
entrez: 22 2 2023
Statut: epublish

Résumé

Protein kinases play a vital role in a wide range of cellular processes, and compounds that inhibit kinase activity emerging as a primary focus for targeted therapy development, especially in cancer. Consequently, efforts to characterize the behavior of kinases in response to inhibitor treatment, as well as downstream cellular responses, have been performed at increasingly large scales. Previous work with smaller datasets have used baseline profiling of cell lines and limited kinome profiling data to attempt to predict small molecule effects on cell viability, but these efforts did not use multi-dose kinase profiles and achieved low accuracy with very limited external validation. This work focuses on two large-scale primary data types, kinase inhibitor profiles and gene expression, to predict the results of cell viability screening. We describe the process by which we combined these data sets, examined their properties in relation to cell viability and finally developed a set of computational models that achieve a reasonably high prediction accuracy (R2 of 0.78 and RMSE of 0.154). Using these models, we identified a set of kinases, several of which are understudied, that are strongly influential in the cell viability prediction models. In addition, we also tested to see if a wider range of multiomics data sets could improve the model results and found that proteomic kinase inhibitor profiles were the single most informative data type. Finally, we validated a small subset of the model predictions in several triple-negative and HER2 positive breast cancer cell lines demonstrating that the model performs well with compounds and cell lines that were not included in the training data set. Overall, this result demonstrates that generic knowledge of the kinome is predictive of very specific cell phenotypes, and has the potential to be integrated into targeted therapy development pipelines.

Identifiants

pubmed: 36809237
doi: 10.1371/journal.pcbi.1010888
pii: PCOMPBIOL-D-22-00783
pmc: PMC9983880
doi:

Substances chimiques

Protein Kinases EC 2.7.-
Antineoplastic Agents 0
Protein Kinase Inhibitors 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1010888

Subventions

Organisme : NCI NIH HHS
ID : U01 CA238475
Pays : United States
Organisme : NIDDK NIH HHS
ID : U24 DK116204
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA233811
Pays : United States

Informations de copyright

Copyright: © 2023 Berginski et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Nat Protoc. 2009;4(8):1184-91
pubmed: 19617889
Nature. 2012 Mar 28;483(7391):603-7
pubmed: 22460905
Nat Rev Drug Discov. 2021 Jul;20(7):551-569
pubmed: 34002056
Nat Biotechnol. 2016 Apr;34(4):419-23
pubmed: 26928769
Cell Syst. 2020 Aug 26;11(2):196-207.e7
pubmed: 32755597
Signal Transduct Target Ther. 2019 Dec 17;4:61
pubmed: 31871778
N Engl J Med. 2014 Dec 4;371(23):2167-77
pubmed: 25470694
Nat Rev Genet. 2010 Jan;11(1):60-74
pubmed: 20019687
Front Pharmacol. 2018 Nov 13;9:1300
pubmed: 30483135
Nucleic Acids Res. 2021 Jan 8;49(D1):D605-D612
pubmed: 33237311
Cancers (Basel). 2020 Mar 20;12(3):
pubmed: 32244867
Nat Rev Drug Discov. 2021 Nov;20(11):839-861
pubmed: 34354255
BMC Bioinformatics. 2021 Jan 6;22(1):13
pubmed: 33407085
Science. 2017 Dec 1;358(6367):
pubmed: 29191878
Signal Transduct Target Ther. 2021 May 31;6(1):201
pubmed: 34054126
Cell. 2012 Apr 13;149(2):307-21
pubmed: 22500798
Nature. 2019 May;569(7757):503-508
pubmed: 31068700
Elife. 2021 May 11;10:
pubmed: 33973518
Cancer Res. 2017 Jul 1;77(13):3564-3576
pubmed: 28446463
Sheng Wu Gong Cheng Xue Bao. 2021 Apr 25;37(4):1346-1359
pubmed: 33973447
Nucleic Acids Res. 2021 Jan 8;49(D1):D529-D535
pubmed: 33079988
Front Genet. 2014 Sep 30;5:342
pubmed: 25324859
Mol Cancer. 2018 Feb 19;17(1):48
pubmed: 29455673
J Med Chem. 2022 Jan 27;65(2):891-892
pubmed: 34941238
Oncotarget. 2018 Jan 29;9(21):15480-15497
pubmed: 29643987
Nat Cancer. 2020 Feb;1(2):235-248
pubmed: 32613204
N Engl J Med. 2003 Mar 13;348(11):994-1004
pubmed: 12637609
N Engl J Med. 2006 Dec 28;355(26):2733-43
pubmed: 17192538
Nat Biotechnol. 2007 Sep;25(9):1035-44
pubmed: 17721511
PLoS One. 2015 Dec 30;10(12):e0146021
pubmed: 26717316
Cell. 2017 Jul 27;170(3):564-576.e16
pubmed: 28753430
Cell. 2020 Jan 23;180(2):387-402.e16
pubmed: 31978347
N Engl J Med. 2001 Mar 15;344(11):783-92
pubmed: 11248153
J Exp Clin Cancer Res. 2019 Apr 11;38(1):156
pubmed: 30975211
Mol Syst Biol. 2017 Nov 3;13(11):951
pubmed: 29101300
Cancer Discov. 2017 Mar;7(3):302-321
pubmed: 28108460
J Natl Cancer Inst Monogr. 2019 Aug 1;2019(53):
pubmed: 31425592
Genome Biol. 2013;14(10):R110
pubmed: 24176112

Auteurs

Matthew E Berginski (ME)

Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.

Chinmaya U Joisa (CU)

Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Chapel Hill, North Carolina, United States of America.

Brian T Golitz (BT)

Eshelman Institute for Innovation, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.

Shawn M Gomez (SM)

Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Chapel Hill, North Carolina, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs
Humans Male Female Health Knowledge, Attitudes, Practice Middle Aged
Humans Neoplasms Male Female Middle Aged
Humans Middle Aged Female Male Surveys and Questionnaires

Classifications MeSH